Research programme: dihydrofolate reductase inhibitors - Serenex
Alternative Names: DHFR inhibitors - Serenex; Dihydrofolate reductase inhibitors research programme - Serenex; SC101150; SC105530Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Serenex
- Class
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 19 Jan 2005 Preclinical trials in Inflammation in USA (unspecified route)